Header Logo

Connection

MANJUSHA GAGLANI to Humans

Back to Details
This is a "connection" page, showing publications MANJUSHA GAGLANI has written about Humans.
MANJUSHA GAGLANI
Connection Strength
1.224
Humans
  1. Protection of Two and Three mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized With COVID-19-VISION Network, August 2021 to March 2022. J Infect Dis. 2023 04 18; 227(8):961-969.
    View in: PubMed
    Score: 0.023
  2. Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial. Clin Infect Dis. 2023 02 08; 76(3):e1168-e1176.
    View in: PubMed
    Score: 0.023
  3. Vaccine Effectiveness Against Acute Respiratory Illness Hospitalizations for Influenza-Associated Pneumonia During the 2015-2016 to 2017-2018 Seasons: US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). Clin Infect Dis. 2022 04 28; 74(8):1329-1337.
    View in: PubMed
    Score: 0.022
  4. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 18; 71(11):422-428.
    View in: PubMed
    Score: 0.022
  5. Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized Open-Label Trial. Clin Infect Dis. 2021 12 06; 73(11):1973-1981.
    View in: PubMed
    Score: 0.021
  6. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med. 2021 07 22; 385(4):320-329.
    View in: PubMed
    Score: 0.021
  7. Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011-2012 to 2016-2017. Clin Infect Dis. 2021 04 08; 72(7):1147-1157.
    View in: PubMed
    Score: 0.020
  8. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 02; 70(13):495-500.
    View in: PubMed
    Score: 0.020
  9. Reply to Yager and Doll. Clin Infect Dis. 2020 12 15; 71(12):3264-3265.
    View in: PubMed
    Score: 0.020
  10. Effects of Repeated Annual Inactivated Influenza Vaccination among Healthcare Personnel on Serum Hemagglutinin Inhibition Antibody Response to A/Perth/16/2009 (H3N2)-like virus during 2010-11. Vaccine. 2016 Feb 10; 34(7):981-8.
    View in: PubMed
    Score: 0.014
  11. Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States. J Infect Dis. 2016 May 15; 213(10):1546-56.
    View in: PubMed
    Score: 0.014
  12. Editorial commentary: school-located influenza vaccination: why worth the effort? Clin Infect Dis. 2014 Aug 01; 59(3):333-5.
    View in: PubMed
    Score: 0.013
  13. Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine. J Infect Dis. 2014 Jun 01; 209(11):1705-14.
    View in: PubMed
    Score: 0.012
  14. Potential influence of seasonal influenza vaccination requirement versus traditional vaccine promotion strategies on unvaccinated healthcare personnel. Vaccine. 2013 Aug 20; 31(37):3915-21.
    View in: PubMed
    Score: 0.012
  15. Subjective social status predicts wintertime febrile acute respiratory illness among women healthcare personnel. Health Psychol. 2014 Mar; 33(3):282-91.
    View in: PubMed
    Score: 0.012
  16. Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J. 2008 May; 27(5):444-52.
    View in: PubMed
    Score: 0.008
  17. Association of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination and Reductions in Post COVID Conditions Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a US Prospective Cohort of Essential Workers. J Infect Dis. 2025 Mar 17; 231(3):665-676.
    View in: PubMed
    Score: 0.007
  18. Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025. MMWR Morb Mortal Wkly Rep. 2025 Feb 27; 74(6):83-90.
    View in: PubMed
    Score: 0.007
  19. Effectiveness of the Original Monovalent Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination Series Against Hospitalization for COVID-19-Associated Venous Thromboembolism. J Infect Dis. 2025 Feb 20; 231(2):378-385.
    View in: PubMed
    Score: 0.007
  20. COVID-19 Vaccination and Odds of Post-COVID-19 Condition Symptoms in Children Aged 5 to 17 Years. JAMA Netw Open. 2025 Feb 03; 8(2):e2459672.
    View in: PubMed
    Score: 0.007
  21. COVID-19 and influenza vaccine Hesitancy among adults hospitalized in the United States, 2019-2022. Vaccine. 2025 Feb 27; 48:126806.
    View in: PubMed
    Score: 0.007
  22. Vaccine effectiveness against influenza-associated hospitalizations in adults with liver disease, 2015-2020: US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). Hum Vaccin Immunother. 2025 Dec; 21(1):2457205.
    View in: PubMed
    Score: 0.007
  23. Methods to Adjust for Confounding in Test-Negative Design COVID-19 Effectiveness Studies: Simulation Study. JMIR Form Res. 2025 Jan 27; 9:e58981.
    View in: PubMed
    Score: 0.007
  24. Protection From COVID-19 Vaccination and Prior SARS-CoV-2 Infection Among Children Aged 6 Months-4 Years, United States, September 2022-April 2023. J Pediatric Infect Dis Soc. 2025 Jan 20; 14(1).
    View in: PubMed
    Score: 0.007
  25. Risk reduction in SARS-CoV-2 infection and reinfection conferred by humoral antibody levels among essential workers during Omicron predominance. PLoS One. 2024; 19(12):e0306953.
    View in: PubMed
    Score: 0.007
  26. Reduced Effectiveness of Repeat Influenza Vaccination: Distinguishing Among Within-Season Waning, Recent Clinical Infection, and Subclinical Infection. J Infect Dis. 2024 Dec 16; 230(6):1309-1318.
    View in: PubMed
    Score: 0.007
  27. Molecular features of the serological IgG repertoire elicited by egg-based, cell-based, or recombinant haemagglutinin-based seasonal influenza vaccines: a comparative, prospective, observational cohort study. Lancet Microbe. 2025 Feb; 6(2):100935.
    View in: PubMed
    Score: 0.007
  28. Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses - IVY Network, September 1, 2022-March 30, 2023. Vaccine. 2025 Jan 01; 43(Pt 2):126492.
    View in: PubMed
    Score: 0.007
  29. Effectiveness of Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Hospitalization and Severe In-Hospital Outcomes Among Adults in the United States, September 2022-August 2023. Influenza Other Respir Viruses. 2024 11; 18(11):e70027.
    View in: PubMed
    Score: 0.007
  30. Elevated body mass index is not significantly associated with reduced influenza vaccine effectiveness. Sci Rep. 2024 09 13; 14(1):21466.
    View in: PubMed
    Score: 0.006
  31. Anti-SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021-June 2022. J Infect Dis. 2024 Jul 25; 230(1):45-54.
    View in: PubMed
    Score: 0.006
  32. Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023. J Infect Dis. 2024 Jul 25; 230(1):141-151.
    View in: PubMed
    Score: 0.006
  33. Hybrid Immunity and SARS-CoV-2 Antibodies: Results of the HEROES-RECOVER Prospective Cohort Study. Clin Infect Dis. 2024 07 19; 79(1):96-107.
    View in: PubMed
    Score: 0.006
  34. Antibody Response to Symptomatic Infection With SARS-CoV-2 Omicron Variant Viruses, December 2021-June 2022. Influenza Other Respir Viruses. 2024 07; 18(7):e13339.
    View in: PubMed
    Score: 0.006
  35. Effectiveness of the influenza vaccine for preventing laboratory-confirmed influenza infections in outpatient immunocompromised adults, 2017-2018. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2354013.
    View in: PubMed
    Score: 0.006
  36. Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022-April 2023. Influenza Other Respir Viruses. 2024 06; 18(6):e13342.
    View in: PubMed
    Score: 0.006
  37. Vaccine Effectiveness Against Influenza A-Associated Hospitalization, Organ Failure, and Death: United States, 2022-2023. Clin Infect Dis. 2024 04 10; 78(4):1056-1064.
    View in: PubMed
    Score: 0.006
  38. Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults. JAMA Netw Open. 2024 04 01; 7(4):e244954.
    View in: PubMed
    Score: 0.006
  39. Vaccine Effectiveness Against Pediatric Influenza-A-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2022-2023 Season: VISION Network. Clin Infect Dis. 2024 03 20; 78(3):746-755.
    View in: PubMed
    Score: 0.006
  40. Post-recovery health domain scores among outpatients by SARS-CoV-2 testing status during the pre-Delta period. BMC Infect Dis. 2024 Mar 08; 24(1):300.
    View in: PubMed
    Score: 0.006
  41. Risk of COVID-19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders. Influenza Other Respir Viruses. 2024 03; 18(3):e13269.
    View in: PubMed
    Score: 0.006
  42. Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States. MMWR Morb Mortal Wkly Rep. 2024 Feb 29; 73(8):168-174.
    View in: PubMed
    Score: 0.006
  43. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged =18 Years - VISION and IVY Networks, September 2023-January 2024. MMWR Morb Mortal Wkly Rep. 2024 Feb 29; 73(8):180-188.
    View in: PubMed
    Score: 0.006
  44. Clinical Epidemiology and Risk Factors for Critical Outcomes Among Vaccinated and Unvaccinated Adults Hospitalized With COVID-19-VISION Network, 10 States, June 2021-March 2023. Clin Infect Dis. 2024 02 17; 78(2):338-348.
    View in: PubMed
    Score: 0.006
  45. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years. JAMA. 2024 02 06; 331(5):408-416.
    View in: PubMed
    Score: 0.006
  46. Longitudinal parental perception of COVID-19 vaccines for children in a multi-site, cohort study. Vaccine. 2024 Mar 07; 42(7):1512-1520.
    View in: PubMed
    Score: 0.006
  47. Redirecting antibody responses from egg-adapted epitopes following repeat vaccination with recombinant or cell culture-based versus egg-based influenza vaccines. Nat Commun. 2024 Jan 04; 15(1):254.
    View in: PubMed
    Score: 0.006
  48. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med. 2004 Jan; 158(1):65-73.
    View in: PubMed
    Score: 0.006
  49. Every nose counts: a new influenza vaccine for all healthy schoolchildren? Clin Pediatr (Phila). 2004 Jan-Feb; 43(1):35-41.
    View in: PubMed
    Score: 0.006
  50. Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design. Vaccine. 2023 Dec 12; 41(51):7581-7586.
    View in: PubMed
    Score: 0.006
  51. Work Attendance with Acute Respiratory Illness Before and During COVID-19 Pandemic, United States, 2018-2022. Emerg Infect Dis. 2023 Dec; 29(12):2442-2450.
    View in: PubMed
    Score: 0.006
  52. Serum per- and polyfluoroalkyl substance concentrations and longitudinal change in post-infection and post-vaccination SARS-CoV-2 antibodies. Environ Res. 2023 Dec 15; 239(Pt 1):117297.
    View in: PubMed
    Score: 0.006
  53. Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged =60 Years - IVY Network, 20 U.S. States, February 2022-May 2023. MMWR Morb Mortal Wkly Rep. 2023 Oct 06; 72(40):1083-1088.
    View in: PubMed
    Score: 0.006
  54. Changing Severity and Epidemiology of Adults Hospitalized With Coronavirus Disease 2019 (COVID-19) in the United States After Introduction of COVID-19 Vaccines, March 2021-August 2022. Clin Infect Dis. 2023 08 22; 77(4):547-557.
    View in: PubMed
    Score: 0.006
  55. Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months-5 Years - VISION Network, United States, July 2022-June 2023. MMWR Morb Mortal Wkly Rep. 2023 Aug 18; 72(33):886-892.
    View in: PubMed
    Score: 0.006
  56. Total and Subgenomic RNA Viral Load in Patients Infected With SARS-CoV-2 Alpha, Delta, and Omicron Variants. J Infect Dis. 2023 08 11; 228(3):235-244.
    View in: PubMed
    Score: 0.006
  57. Vaccine Effectiveness Against Influenza-Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2021-2022 Season, VISION Network. J Infect Dis. 2023 07 14; 228(2):185-195.
    View in: PubMed
    Score: 0.006
  58. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023. Am J Transplant. 2023 07; 23(7):1062-1076.
    View in: PubMed
    Score: 0.006
  59. Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19-Associated Encounters in Adults During Delta and Omicron Predominance. J Infect Dis. 2023 06 15; 227(12):1348-1363.
    View in: PubMed
    Score: 0.006
  60. Prevalence and Clinical Outcomes of Respiratory Syncytial Virus vs Influenza in Adults Hospitalized With Acute Respiratory Illness From a Prospective Multicenter Study. Clin Infect Dis. 2023 06 08; 76(11):1980-1988.
    View in: PubMed
    Score: 0.006
  61. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023. MMWR Morb Mortal Wkly Rep. 2023 May 26; 72(21):579-588.
    View in: PubMed
    Score: 0.006
  62. Severe Acute Respiratory Syndrome Coronavirus 2 Infection History and Antibody Response to 3 Coronavirus Disease 2019 Messenger RNA Vaccine Doses. Clin Infect Dis. 2023 05 24; 76(10):1822-1831.
    View in: PubMed
    Score: 0.006
  63. Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021. Vaccine. 2023 08 23; 41(37):5424-5434.
    View in: PubMed
    Score: 0.006
  64. Comparison of mRNA vaccine effectiveness against COVID-19-associated hospitalization by vaccination source: Immunization information systems, electronic medical records, and self-report-IVY Network, February 1-August 31, 2022. Vaccine. 2023 06 29; 41(29):4249-4256.
    View in: PubMed
    Score: 0.006
  65. Relationships Between Social Vulnerability and Coronavirus Disease 2019 Vaccination Coverage and Vaccine Effectiveness. Clin Infect Dis. 2023 05 03; 76(9):1615-1625.
    View in: PubMed
    Score: 0.006
  66. Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents. Pediatrics. 2023 05 01; 151(5).
    View in: PubMed
    Score: 0.006
  67. Prior SARS-CoV-2 infection and COVID-19 vaccine effectiveness against outpatient illness during widespread circulation of SARS-CoV-2 Omicron variant, US Flu VE network. Influenza Other Respir Viruses. 2023 05; 17(5):e13143.
    View in: PubMed
    Score: 0.006
  68. Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period - IVY Network, 19 U.S. States, February 1, 2022-January 31, 2023. MMWR Morb Mortal Wkly Rep. 2023 Apr 28; 72(17):463-468.
    View in: PubMed
    Score: 0.006
  69. Influenza Vaccine Effectiveness Against Influenza A(H3N2)-Related Illness in the United States During the 2021-2022 Influenza Season. Clin Infect Dis. 2023 04 17; 76(8):1358-1363.
    View in: PubMed
    Score: 0.006
  70. Influenza Vaccine Effectiveness Among Children: 2011-2020. Pediatrics. 2023 04 01; 151(4).
    View in: PubMed
    Score: 0.006
  71. Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022. Clin Infect Dis. 2023 03 21; 76(6):1030-1037.
    View in: PubMed
    Score: 0.006
  72. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2023 Mar 17; 71(53):1637-1646.
    View in: PubMed
    Score: 0.006
  73. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open. 2023 03 01; 6(3):e232598.
    View in: PubMed
    Score: 0.006
  74. Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States. Clin Infect Dis. 2023 02 08; 76(3):e460-e468.
    View in: PubMed
    Score: 0.006
  75. Risk Factors for Reinfection with SARS-CoV-2 Omicron Variant among Previously Infected Frontline Workers. Emerg Infect Dis. 2023 03; 29(3):599-604.
    View in: PubMed
    Score: 0.006
  76. Relationship between Telework Experience and Presenteeism during COVID-19 Pandemic, United States, March-November 2020. Emerg Infect Dis. 2023 02; 29(2):278-285.
    View in: PubMed
    Score: 0.006
  77. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged =65 Years - IVY Network, 18 States, September 8-November 30, 2022. MMWR Morb Mortal Wkly Rep. 2022 Dec 30; 71(5152):1625-1630.
    View in: PubMed
    Score: 0.006
  78. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022 Dec 30; 71(5152):1616-1624.
    View in: PubMed
    Score: 0.006
  79. Burden of medically attended influenza infection and cases averted by vaccination - United States, 2016/17 through 2018/19 influenza seasons. Vaccine. 2022 12 12; 40(52):7703-7708.
    View in: PubMed
    Score: 0.006
  80. Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States. Vaccine. 2022 11 15; 40(48):6979-6986.
    View in: PubMed
    Score: 0.006
  81. Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022. MMWR Morb Mortal Wkly Rep. 2022 Oct 21; 71(42):1327-1334.
    View in: PubMed
    Score: 0.006
  82. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022. MMWR Morb Mortal Wkly Rep. 2022 Oct 21; 71(42):1335-1342.
    View in: PubMed
    Score: 0.006
  83. Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers. JAMA. 2022 10 18; 328(15):1523-1533.
    View in: PubMed
    Score: 0.006
  84. Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study. BMJ. 2022 10 11; 379:e072065.
    View in: PubMed
    Score: 0.006
  85. Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States. Clin Infect Dis. 2022 10 03; 75(Suppl 2):S159-S166.
    View in: PubMed
    Score: 0.006
  86. Multiplex Detection of Antibody Landscapes to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/Influenza/Common Human Coronaviruses Following Vaccination or Infection With SARS-CoV-2 and Influenza. Clin Infect Dis. 2022 10 03; 75(Suppl 2):S271-S284.
    View in: PubMed
    Score: 0.006
  87. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 2022 10 03; 379:e072141.
    View in: PubMed
    Score: 0.006
  88. mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients. J Infect Dis. 2022 09 13; 226(5):797-807.
    View in: PubMed
    Score: 0.006
  89. Parental Intentions and Perceptions Toward COVID-19 Vaccination Among Children Aged 4 Months to 4 Years - PROTECT Cohort, Four States, July 2021-May 2022. MMWR Morb Mortal Wkly Rep. 2022 09 02; 71(35):1109-1114.
    View in: PubMed
    Score: 0.006
  90. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States. JAMA Netw Open. 2022 09 01; 5(9):e2233273.
    View in: PubMed
    Score: 0.006
  91. Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection. Clin Infect Dis. 2022 08 24; 75(1):e827-e837.
    View in: PubMed
    Score: 0.006
  92. Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-Related outpatient illness among adults, October 2021-February 2022. Influenza Other Respir Viruses. 2022 11; 16(6):975-985.
    View in: PubMed
    Score: 0.006
  93. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022. MMWR Morb Mortal Wkly Rep. 2022 Jul 22; 71(29):931-939.
    View in: PubMed
    Score: 0.006
  94. Ascertainment of vaccination status by self-report versus source documentation: Impact on measuring COVID-19 vaccine effectiveness. Influenza Other Respir Viruses. 2022 11; 16(6):1101-1111.
    View in: PubMed
    Score: 0.006
  95. COVID-19 Vaccination Perspectives and Illnesses Among Law Enforcement Officers, Firefighters, and Other First Responders in the US, January to September 2021. JAMA Netw Open. 2022 07 01; 5(7):e2222640.
    View in: PubMed
    Score: 0.006
  96. Vaccine-associated attenuation of subjective severity among outpatients with influenza. Vaccine. 2022 07 30; 40(32):4322-4327.
    View in: PubMed
    Score: 0.006
  97. Detection and Stability of SARS-CoV-2 in Three Self-Collected Specimen Types: Flocked Midturbinate Swab (MTS) in Viral Transport Media, Foam MTS, and Saliva. Microbiol Spectr. 2022 06 29; 10(3):e0103322.
    View in: PubMed
    Score: 0.006
  98. Effectiveness of mRNA Vaccines Against COVID-19 Hospitalization by Age and Chronic Medical Conditions Burden Among Immunocompetent US Adults, March-August 2021. J Infect Dis. 2022 05 16; 225(10):1694-1700.
    View in: PubMed
    Score: 0.006
  99. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States. Clin Infect Dis. 2022 05 03; 74(9):1515-1524.
    View in: PubMed
    Score: 0.005
  100. Consistency of self-reported and documented historical influenza vaccination status of US healthcare workers. Influenza Other Respir Viruses. 2022 09; 16(5):881-890.
    View in: PubMed
    Score: 0.005
  101. Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers. N Engl J Med. 2022 05 12; 386(19):1855-1857.
    View in: PubMed
    Score: 0.005
  102. Rationale and approach to target children with asthma for annual influenza immunization. Semin Pediatr Infect Dis. 2002 Apr; 13(2):97-103.
    View in: PubMed
    Score: 0.005
  103. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep. 2022 Apr 01; 71(13):495-502.
    View in: PubMed
    Score: 0.005
  104. Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 25; 71(12):459-465.
    View in: PubMed
    Score: 0.005
  105. Interim Estimates of 2021-22 Seasonal Influenza Vaccine Effectiveness - United States, February 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 11; 71(10):365-370.
    View in: PubMed
    Score: 0.005
  106. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022 03 09; 376:e069761.
    View in: PubMed
    Score: 0.005
  107. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 04; 71(9):352-358.
    View in: PubMed
    Score: 0.005
  108. Role of Age in the Spread of Influenza, 2011-2019: Data From the US Influenza Vaccine Effectiveness Network. Am J Epidemiol. 2022 02 19; 191(3):465-471.
    View in: PubMed
    Score: 0.005
  109. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18; 71(7):255-263.
    View in: PubMed
    Score: 0.005
  110. Vaccine effectiveness against COVID-19 among symptomatic persons aged =12?years with reported contact with COVID-19 cases, February-September 2021. Influenza Other Respir Viruses. 2022 07; 16(4):673-679.
    View in: PubMed
    Score: 0.005
  111. Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 28; 71(4):118-124.
    View in: PubMed
    Score: 0.005
  112. Clinical Influenza Testing Practices in Hospitalized Children at United States Medical Centers, 2015-2018. J Pediatric Infect Dis Soc. 2022 Jan 27; 11(1):5-8.
    View in: PubMed
    Score: 0.005
  113. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Jan 21; 71(4):139-145.
    View in: PubMed
    Score: 0.005
  114. Incidence of SARS-CoV-2 infection among COVID-19 vaccinated and unvaccinated healthcare personnel, first responders, and other essential and frontline workers: Eight US locations, January-September 2021. Influenza Other Respir Viruses. 2022 05; 16(3):585-593.
    View in: PubMed
    Score: 0.005
  115. Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-Nine States, January-September 2021. Am J Transplant. 2022 01; 22(1):306-314.
    View in: PubMed
    Score: 0.005
  116. Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021. MMWR Morb Mortal Wkly Rep. 2021 Dec 31; 70(5152):1761-1765.
    View in: PubMed
    Score: 0.005
  117. Coronavirus disease 2019 (COVID-19) Versus Influenza in Hospitalized Adult Patients in the United States: Differences in Demographic and Severity Indicators. Clin Infect Dis. 2021 12 16; 73(12):2240-2247.
    View in: PubMed
    Score: 0.005
  118. COVID-19 vaccine perceptions and uptake in a national prospective cohort of essential workers. Vaccine. 2022 01 24; 40(3):494-502.
    View in: PubMed
    Score: 0.005
  119. Effect of Antigenic Drift on Influenza Vaccine Effectiveness in the United States-2019-2020. Clin Infect Dis. 2021 12 06; 73(11):e4244-e4250.
    View in: PubMed
    Score: 0.005
  120. Effectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Immunocompromised Adults. Clin Infect Dis. 2021 12 06; 73(11):e4353-e4360.
    View in: PubMed
    Score: 0.005
  121. A computerized reminder strategy is effective for annual influenza immunization of children with asthma or reactive airway disease. Pediatr Infect Dis J. 2001 Dec; 20(12):1155-60.
    View in: PubMed
    Score: 0.005
  122. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA. 2021 11 23; 326(20):2043-2054.
    View in: PubMed
    Score: 0.005
  123. Messenger RNA Vaccine Effectiveness Against Coronavirus Disease 2019 Among Symptomatic Outpatients Aged =16 Years in the United States, February-May 2021. J Infect Dis. 2021 11 22; 224(10):1694-1698.
    View in: PubMed
    Score: 0.005
  124. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1539-1544.
    View in: PubMed
    Score: 0.005
  125. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
    View in: PubMed
    Score: 0.005
  126. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021. MMWR Morb Mortal Wkly Rep. 2021 Sep 24; 70(38):1337-1343.
    View in: PubMed
    Score: 0.005
  127. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N Engl J Med. 2021 10 07; 385(15):1355-1371.
    View in: PubMed
    Score: 0.005
  128. Influenza Vaccine Effectiveness Against Hospitalization in the United States, 2019-2020. J Infect Dis. 2021 09 01; 224(5):813-820.
    View in: PubMed
    Score: 0.005
  129. Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance - Eight U.S. Locations, December 2020-August 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 27; 70(34):1167-1169.
    View in: PubMed
    Score: 0.005
  130. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 27; 70(34):1156-1162.
    View in: PubMed
    Score: 0.005
  131. Waning Vaccine Effectiveness Against Influenza-Associated Hospitalizations Among Adults, 2015-2016 to 2018-2019, United States Hospitalized Adult Influenza Vaccine Effectiveness Network. Clin Infect Dis. 2021 08 16; 73(4):726-729.
    View in: PubMed
    Score: 0.005
  132. Influenza Vaccine Effectiveness in Inpatient and Outpatient Settings in the United States, 2015-2018. Clin Infect Dis. 2021 08 02; 73(3):386-392.
    View in: PubMed
    Score: 0.005
  133. Effects of Prior Season Vaccination on Current Season Vaccine Effectiveness in the United States Flu Vaccine Effectiveness Network, 2012-2013 Through 2017-2018. Clin Infect Dis. 2021 08 02; 73(3):497-505.
    View in: PubMed
    Score: 0.005
  134. Vaccine Effectiveness Against Influenza-Associated Hospitalizations Among Adults, 2018-2019, US Hospitalized Adult Influenza Vaccine Effectiveness Network. J Infect Dis. 2021 07 02; 224(1):151-163.
    View in: PubMed
    Score: 0.005
  135. Low Influenza Vaccine Effectiveness Against A(H3N2)-Associated Hospitalizations in 2016-2017 and 2017-2018 of the Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). J Infect Dis. 2021 06 15; 223(12):2062-2071.
    View in: PubMed
    Score: 0.005
  136. Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States. Vaccine. 2021 06 08; 39(25):3324-3328.
    View in: PubMed
    Score: 0.005
  137. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged =65 Years - United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021 May 07; 70(18):674-679.
    View in: PubMed
    Score: 0.005
  138. Systematic Testing for Influenza and Coronavirus Disease 2019 Among Patients With Respiratory Illness. Clin Infect Dis. 2021 05 04; 72(9):e426-e428.
    View in: PubMed
    Score: 0.005
  139. Differences between Frequentist and Bayesian inference in routine surveillance for influenza vaccine effectiveness: a test-negative case-control study. BMC Public Health. 2021 03 16; 21(1):516.
    View in: PubMed
    Score: 0.005
  140. Relative and Absolute Effectiveness of High-Dose and Standard-Dose Influenza Vaccine Against Influenza-Related Hospitalization Among Older Adults-United States, 2015-2017. Clin Infect Dis. 2021 03 15; 72(6):995-1003.
    View in: PubMed
    Score: 0.005
  141. Influenza vaccination coverage among persons seeking outpatient medical care for acute respiratory illness in five states in the United States, 2011-2012 through 2018-2019. Vaccine. 2021 03 19; 39(12):1788-1796.
    View in: PubMed
    Score: 0.005
  142. Reducing Antibiotic Use in Ambulatory Care Through Influenza Vaccination. Clin Infect Dis. 2020 12 31; 71(11):e726-e734.
    View in: PubMed
    Score: 0.005
  143. Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015-16 to 2018-19. Vaccine. 2020 09 29; 38(42):6562-6569.
    View in: PubMed
    Score: 0.005
  144. Patterns of Influenza Vaccination and Vaccine Effectiveness Among Young US Children Who Receive Outpatient Care for Acute Respiratory Tract Illness. JAMA Pediatr. 2020 07 01; 174(7):705-713.
    View in: PubMed
    Score: 0.005
  145. Influenza vaccine effectiveness among outpatients in the US Influenza Vaccine Effectiveness Network by study site 2011-2016. Influenza Other Respir Viruses. 2020 07; 14(4):380-390.
    View in: PubMed
    Score: 0.005
  146. Interim Estimates of 2019-20 Seasonal Influenza Vaccine Effectiveness - United States, February 2020. MMWR Morb Mortal Wkly Rep. 2020 Feb 21; 69(7):177-182.
    View in: PubMed
    Score: 0.005
  147. Spread of Antigenically Drifted Influenza A(H3N2) Viruses and Vaccine Effectiveness in the United States During the 2018-2019 Season. J Infect Dis. 2020 01 01; 221(1):8-15.
    View in: PubMed
    Score: 0.005
  148. Paid Leave and Access to Telework as Work Attendance Determinants during Acute Respiratory Illness, United States, 2017-2018. Emerg Infect Dis. 2020 01; 26(1).
    View in: PubMed
    Score: 0.005
  149. Effects of Influenza Vaccination in the United States During the 2017-2018 Influenza Season. Clin Infect Dis. 2019 11 13; 69(11):1845-1853.
    View in: PubMed
    Score: 0.005
  150. Prevention of Influenza Hospitalization Among Adults in the United States, 2015-2016: Results From the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). J Infect Dis. 2019 09 13; 220(8):1265-1275.
    View in: PubMed
    Score: 0.005
  151. Influenza Vaccine Effectiveness in the United States During the 2016-2017 Season. Clin Infect Dis. 2019 05 17; 68(11):1798-1806.
    View in: PubMed
    Score: 0.004
  152. Influenza Vaccine Effectiveness and Statin Use Among Adults in the United States, 2011-2017. Clin Infect Dis. 2019 05 02; 68(10):1616-1622.
    View in: PubMed
    Score: 0.004
  153. Picture of the month. Mycobacterium marinum facial abscess. Arch Pediatr Adolesc Med. 1999 May; 153(5):543-4.
    View in: PubMed
    Score: 0.004
  154. Interim Estimates of 2018-19 Seasonal Influenza Vaccine Effectiveness - United States, February 2019. MMWR Morb Mortal Wkly Rep. 2019 Feb 15; 68(6):135-139.
    View in: PubMed
    Score: 0.004
  155. Hospitalization following outpatient medical care for influenza: US influenza vaccine effectiveness network, 2011-12-2015-16. Influenza Other Respir Viruses. 2019 03; 13(2):133-137.
    View in: PubMed
    Score: 0.004
  156. Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012-2016. Vaccine. 2018 12 18; 36(52):8047-8053.
    View in: PubMed
    Score: 0.004
  157. Association of Prior Vaccination With Influenza Vaccine Effectiveness in Children Receiving Live Attenuated or Inactivated Vaccine. JAMA Netw Open. 2018 10 05; 1(6):e183742.
    View in: PubMed
    Score: 0.004
  158. Influence of Birth Cohort on Effectiveness of 2015-2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States. J Infect Dis. 2018 06 20; 218(2):189-196.
    View in: PubMed
    Score: 0.004
  159. Outpatient Antibiotic Prescribing for Acute Respiratory Infections During Influenza Seasons. JAMA Netw Open. 2018 06 01; 1(2):e180243.
    View in: PubMed
    Score: 0.004
  160. Influenza Antiviral Prescribing for Outpatients With an Acute Respiratory Illness and at High Risk for Influenza-Associated Complications During 5 Influenza Seasons-United States, 2011-2016. Clin Infect Dis. 2018 03 19; 66(7):1035-1041.
    View in: PubMed
    Score: 0.004
  161. Influenza vaccine effectiveness in older adults compared with younger adults over five seasons. Vaccine. 2018 02 28; 36(10):1272-1278.
    View in: PubMed
    Score: 0.004
  162. Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018. MMWR Morb Mortal Wkly Rep. 2018 Feb 16; 67(6):180-185.
    View in: PubMed
    Score: 0.004
  163. 2015-2016 Vaccine Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children in the United States. Clin Infect Dis. 2018 02 10; 66(5):665-672.
    View in: PubMed
    Score: 0.004
  164. Burden of medically attended influenza infection and cases averted by vaccination - United States, 2013/14 through 2015/16 influenza seasons. Vaccine. 2018 01 25; 36(4):467-472.
    View in: PubMed
    Score: 0.004
  165. Contribution of antibody to neutrophil-mediated killing of Enterococcus faecalis. J Clin Immunol. 1997 Nov; 17(6):478-84.
    View in: PubMed
    Score: 0.004
  166. Influenza Vaccine Effectiveness in the United States during the 2015-2016 Season. N Engl J Med. 2017 08 10; 377(6):534-543.
    View in: PubMed
    Score: 0.004
  167. Prior-Season Vaccination and Risk of Influenza During the 2014-2015 Season in the United States. J Infect Dis. 2017 07 15; 216(2):284-285.
    View in: PubMed
    Score: 0.004
  168. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children during the 2014-2015 season. Vaccine. 2017 05 09; 35(20):2685-2693.
    View in: PubMed
    Score: 0.004
  169. Interim Estimates of 2016-17 Seasonal Influenza Vaccine Effectiveness - United States, February 2017. MMWR Morb Mortal Wkly Rep. 2017 Feb 17; 66(6):167-171.
    View in: PubMed
    Score: 0.004
  170. Chronic osteomyelitis caused by Clostridium difficile in an adolescent with sickle cell disease. Pediatr Infect Dis J. 1996 Nov; 15(11):1054-6.
    View in: PubMed
    Score: 0.004
  171. 2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type. Clin Infect Dis. 2016 Dec 15; 63(12):1564-1573.
    View in: PubMed
    Score: 0.004
  172. Reduced serologic sensitivity to influenza A virus illness among inactivated influenza vaccinees. Vaccine. 2016 06 24; 34(30):3443-6.
    View in: PubMed
    Score: 0.004
  173. Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015. J Infect Dis. 2016 10 01; 214(7):1010-9.
    View in: PubMed
    Score: 0.004
  174. Infections complicating lawn mower injuries in children. Pediatr Infect Dis J. 1996 May; 15(5):452-5.
    View in: PubMed
    Score: 0.004
  175. Neonatal radiology casebook. Retropharyngeal abscess in the neonate. J Perinatol. 1996 May-Jun; 16(3 Pt 1):231-3.
    View in: PubMed
    Score: 0.004
  176. Influenza Vaccine Effectiveness for Fully and Partially Vaccinated Children 6 Months to 8 Years Old During 2011-2012 and 2012-2013: The Importance of Two Priming Doses. Pediatr Infect Dis J. 2016 Mar; 35(3):299-308.
    View in: PubMed
    Score: 0.004
  177. Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine. Pediatrics. 2016 Feb; 137(2):e20153279.
    View in: PubMed
    Score: 0.004
  178. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in the United States. Vaccine. 2016 Jan 02; 34(1):77-82.
    View in: PubMed
    Score: 0.004
  179. Illness Severity and Work Productivity Loss Among Working Adults With Medically Attended Acute Respiratory Illnesses: US Influenza Vaccine Effectiveness Network 2012-2013. Clin Infect Dis. 2016 Feb 15; 62(4):448-455.
    View in: PubMed
    Score: 0.004
  180. Factors associated with real-time RT-PCR cycle threshold values among medically attended influenza episodes. J Med Virol. 2016 Apr; 88(4):719-23.
    View in: PubMed
    Score: 0.003
  181. Incidence of medically attended influenza infection and cases averted by vaccination, 2011/2012 and 2012/2013 influenza seasons. Vaccine. 2015 Sep 22; 33(39):5181-7.
    View in: PubMed
    Score: 0.003
  182. Clinical indicators of childhood retropharyngeal abscess. Am J Emerg Med. 1995 May; 13(3):333-6.
    View in: PubMed
    Score: 0.003
  183. Use of influenza antiviral medications among outpatients at high risk for influenza-associated complications during the 2013-2014 influenza season. Clin Infect Dis. 2015 Jun 01; 60(11):1677-80.
    View in: PubMed
    Score: 0.003
  184. Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morb Mortal Wkly Rep. 2015 Jan 16; 64(1):10-5.
    View in: PubMed
    Score: 0.003
  185. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015 May 15; 211(10):1529-40.
    View in: PubMed
    Score: 0.003
  186. Use of influenza antiviral agents by ambulatory care clinicians during the 2012-2013 influenza season. Clin Infect Dis. 2014 Sep 15; 59(6):774-82.
    View in: PubMed
    Score: 0.003
  187. Barriers and facilitators to influenza vaccination and vaccine coverage in a cohort of health care personnel. Am J Infect Control. 2014 Apr; 42(4):371-5.
    View in: PubMed
    Score: 0.003
  188. Comparison of laboratory-confirmed influenza and noninfluenza acute respiratory illness in healthcare personnel during the 2010-2011 influenza season. Infect Control Hosp Epidemiol. 2014 May; 35(5):538-46.
    View in: PubMed
    Score: 0.003
  189. Interim estimates of 2013-14 seasonal influenza vaccine effectiveness - United States, February 2014. MMWR Morb Mortal Wkly Rep. 2014 Feb 21; 63(7):137-42.
    View in: PubMed
    Score: 0.003
  190. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014 Feb; 58(3):319-27.
    View in: PubMed
    Score: 0.003
  191. Consistency of influenza A virus detection test results across respiratory specimen collection methods using real-time reverse transcription-PCR. J Clin Microbiol. 2013 Nov; 51(11):3880-2.
    View in: PubMed
    Score: 0.003
  192. Changes in self-rated health and subjective social status over time in a cohort of healthcare personnel. J Health Psychol. 2014 Sep; 19(9):1185-96.
    View in: PubMed
    Score: 0.003
  193. The expected emotional benefits of influenza vaccination strongly affect pre-season intentions and subsequent vaccination among healthcare personnel. Vaccine. 2012 May 21; 30(24):3557-65.
    View in: PubMed
    Score: 0.003
  194. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age. Pediatr Infect Dis J. 2011 Oct; 30(10):e179-85.
    View in: PubMed
    Score: 0.003
  195. Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. J Infect Dis. 2010 Dec 01; 202(11):1626-33.
    View in: PubMed
    Score: 0.002
  196. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis. 2010 Mar 17; 10:71.
    View in: PubMed
    Score: 0.002
  197. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics. 2007 Sep; 120(3):e553-64.
    View in: PubMed
    Score: 0.002
  198. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine. 2007 May 16; 25(20):4038-45.
    View in: PubMed
    Score: 0.002
  199. Effectiveness of school-based influenza vaccination. N Engl J Med. 2006 Dec 14; 355(24):2523-32.
    View in: PubMed
    Score: 0.002
  200. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics. 2005 Sep; 116(3):e397-407.
    View in: PubMed
    Score: 0.002
  201. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine. 2005 Feb 18; 23(13):1540-8.
    View in: PubMed
    Score: 0.002
  202. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol. 2003 Aug 15; 158(4):305-11.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.